Heterocyclic Building Blocks-Naphthyridine

On June 30, 2016, Inukai, Takayuki; Takeuchi, Jun; Yasuhiro, Tomoko published a patent.Electric Literature of 869640-41-5 The title of the patent was Preparation of quinoline derivatives for the treatment of Axl-related diseases. And the patent contained the following:

The present invention provides quinoline derivatives I [R1 = (un)substituted alkyl, carbocycle or heterocycle; R2 = (un)substituted alkyl, alkenyl, alkynyl, carbocycle, etc.; R3 = alkyl, halogen, haloalkyl or OR31; R4 = alkoxy, haloalkyl, alkyl, alkenyloxy, etc.; R31 = H, alkyl or haloalkyl; A = CH or N; L = O, NH, C(O), S, etc.; ring 1 = 5- to 7-membered cyclic group; m = 0-3; n = 0-3; q = 0-4] or their salts. For example, 2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxylic acid was subjected to reaction with hydroxylamine hydrochloride followed by coupling with 5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinamine to provide N-[(5E)-5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-5-(hydroxyimino)-2-oxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, which underwent Beckmann rearrangement to provide compound II. Compound II exhibited inhibitory activity against Axl with an IC50 value of 0.0015 μM. The invention compounds have strong Axl inhibitory activities and can be useful as therapeutic agents for Axl-related diseases, for example, cancers such as acute myeloid leukemia, chronic myeloid leukemia, melanoma, breast cancer, pancreatic cancer and glioma, kidney diseases, immune system diseases and cardiovascular diseases. The experimental process involved the reaction of 7-Benzyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2(1H)-one(cas: 869640-41-5).Electric Literature of 869640-41-5

The Article related to quinoline derivative preparation axl inhibitor cancer treatment, kidney disease immune system disease cardiovascular disease treatment, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Electric Literature of 869640-41-5

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On March 7, 2002, Ish, Kumar Khanna; Yi, Yu; Balekudru, Devadas; Hwang-Fun, Lu; Nizal, S. Chandrakumar published a patent.Product Details of 445490-78-8 The title of the patent was Compounds containing a pyridinylaminopropoxybicyclic ring system useful as αvβ3 antagonists. And the patent contained the following:

Title compounds were prepared for use as selective inhibitors or antagonists of the αvβ3 and/or αvβ5 integrin. Thus, the benzoxazepine I was prepared by treating 4-benzyloxysalicylaldehyde with BrCMe2CO2CH2Ph and H2NCH2CO2CMe3, debenzylating, cyclizing, reaction with 2-(3-hydroxypropylamino)pyridine 1-oxide, reduction of the N-oxide, and ester hydrolysis. The compounds showed activity in several vitronectin receptor assays. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).Product Details of 445490-78-8

The Article related to pyridinylaminopropoxy bicyclic compound preparation vitronectin receptor antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Other 7-Membered Rings and other aspects.Product Details of 445490-78-8

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On February 7, 2019, Huang, Peter Qinhua; Boren, Brant Clayton; Bunker, Kevin Duane; Liu, Hui; Paliwal, Sunil published a patent.Application of 869640-41-5 The title of the patent was Preparation of pyrazolopyrimidinones and salts thereof as WEE1 kinase inhibitors useful in treatment of cancer and other proliferative diseases. And the patent contained the following:

The invention relates to prepn of pyrazolopyrimidinones and salts thereof as WEE1 kinase inhibitors. The example compound I was prepared accordingby a procedure (procedure given). The compounds of the invention were evaluated for their biol. activity (data given). The compounds of the invention, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer. The experimental process involved the reaction of 7-Benzyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2(1H)-one(cas: 869640-41-5).Application of 869640-41-5

The Article related to pyrazolopyrimidinone preparation wee1 kinase inhibitor antitumor antiproliferative, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Application of 869640-41-5

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On April 1, 2021, Benz, Joerg; Gobbi, Luca; Grether, Uwe; Hanlon, Steven Paul; Hornsperger, Benoit; Kroll, Carsten; Kuhn, Bernd; Kuratli, Martin; Liu, Guofu; O’Hara, Fionn; Richter, Hans; Ritter, Martin published a patent.Quality Control of 7-Benzyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2(1H)-one The title of the patent was Heterocyclic compounds as MAGL inhibitors and their preparation. And the patent contained the following:

The invention provides heterocyclic compounds of formula I, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds Compounds of formula I wherein U is CH2; V is O, NH, CH2, S, SO, SO2, CHOH, CHF and CF2; W is CR’ and CH; X is CH and COH; WX and UV can be taken together to form C:C; both E and G are absent and CH2; Z is CH and N; Q is CR” and N; L is a bond, CHR5, O, OCH2, CH2O, CH2OCH2, etc.; A is C6-14 aryl, 5- to 14-membered heteroaryl and 3- to 14-membered heterocyclyl; R1 and R2 are independently H, halo and C1-6 alkyl; R1R2 can be taken together to form C3-10 cycloalkyl; R3 and R4 are independently H, halo, SF5, CN, etc.; R5 is H and C6-14 aryl; R’ is halo and C1-6 alkyl; R” is H, halo, OH, C1-6 haloalkyl and C1-6 alkyl; with provisions; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by amidation of bis(trichloromethyl) carbonate with (4aR,8S,8aS)-8-methylhexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one with 3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine 4-methylbenzenesulfonate. The invention compounds were evaluated for their MAGL inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value of 4.4 nM. The experimental process involved the reaction of 7-Benzyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2(1H)-one(cas: 869640-41-5).Quality Control of 7-Benzyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2(1H)-one

The Article related to heterocycle preparation magl inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Oxazines (Including Morpholine) and other aspects.Quality Control of 7-Benzyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2(1H)-one

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On April 2, 2015, Fukunaga, Hirofumi; Dozono, Hiroyuki; Hino, Akihiro; Oshikiri, Shinobu; Nagano, Akio published a patent.Synthetic Route of 445490-78-8 The title of the patent was Preparation of nitrogen-containing compounds or their metal complexes as therapeutic and radiodiagnostic agents for integrin-related disorders. And the patent contained the following:

The nitrogen-containing compounds, their salts, or their metal complexes are represented by formula I [A1 = chelate group; R1, R2 = H, (un)substituted C1-6 alkyl, amino protective group; Z1-Z5 = N, CR3; R3 = H, halo, (un)substituted C1-6 alkyl, (un)substituted pyridinyl-containing sulfonyl group; L1 = [NR13(CR14CR15O)qCR16CO]r; L2, L3 = (un)substituted C1-6 alkylene; R13 = H, (un)substituted C1-6 alkyl, amino protective group; R14, R15 = H, (un)substituted C1-6 alkyl; R16 = H, (un)substituted C1-6 alkyl, aromatic or heterocycle amide-containing group]. Thus, reacting tetrahydronaphthyridine terminal-containing cysteic acid (preparation given) with tri-tert-Bu 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate, and deprotecting tert-Bu groups with aqueous LiOH, gave tetraazacyclododecane ring-containing tricarboxylic acid. The tetraazacyclododecane ring-containing tricarboxylic acid can give complexes with radioactive metals showing high concentration and retention in the cancer cells. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).Synthetic Route of 445490-78-8

The Article related to heterocycle metal complex preparation integrin disorder cancer radiodiagnostic, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.Synthetic Route of 445490-78-8

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On May 17, 2018, Devasthale, Pratik; Moore, Fang; Zhao, Guohua; Pieniazek, Susan Nicole; Selvakumar, Kumaravel; Dhanusu, Suresh; Panda, Manoranjan; Marcin, Lawrence R. published a patent.Application In Synthesis of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate The title of the patent was Cyclobutane- and azetidine-containing mono- and spirocyclic compounds as alpha v integrin inhibitors and their preparation. And the patent contained the following:

The invention provides compounds of formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathol. fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions Compounds of formula I wherein A is a covalent bond, CO, O, C1-3 alkoxy, CONH and derivatives, etc.; E is cyclobutylene, azetidinylene, and [3.3.0]bicyclic moiety; X is C1-5 alkylene and (un)substituted phenylene; Y is a bond, CO, O, NH and derivatives, etc.; R1 is (un)substituted imidazolylamino, (un)substituted pyridinylamino, (un)substituted benzimidazolylamino, guanidino, etc.; R3 is H, C1-6 alkyl, C3-10 cycloalkyl, C6-10 aryl, etc.; R4 is H, halo, C1-6 alkyl, C3-10 carbocyclyl,e tc.; R4a is H, halo and C1-6 alkyl, R5 is H, C1-6 alkyl, Ph, benzyl, etc.; Z is N and CH; and pharmaceutically acceptable salts thereof, are claimed. Example compound II•TFA was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their αVβ6 inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value of 420 nM. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).Application In Synthesis of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate

The Article related to cyclobutane azetidine containing spirocycle preparation alpha v integrin inhibitor, Heterocyclic Compounds (One Hetero Atom): Spiro Compounds With One Hetero Atom In Each Ring and other aspects.Application In Synthesis of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On May 16, 2005, Leonard, Kristi; Pan, Wenxi; Anaclerio, Beth; Gushue, Joan M.; Guo, Zihong; DesJarlais, Renee L.; Chaikin, Marge A.; Lattanze, Jennifer; Crysler, Carl; Manthey, Carl L.; Tomczuk, Bruce E.; Marugan, Juan Jose published an article.SDS of cas: 445490-78-8 The title of the article was Non-peptidic αvβ3 antagonists containing indol-1-ylpropionic acids. And the article contained the following:

The synthesis and structure/activity relationship of RGD mimetics that are potent inhibitors of the integrin αvβ3 are described. Indol-1-ylpropionic acids containing a variety of basic moieties at the 5-position, as well as substitutions alpha and beta to the carboxy terminus were synthesized and evaluated. Novel compounds with improved potency have been identified. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).SDS of cas: 445490-78-8

The Article related to indolylpropionic acid preparation vitronectin receptor antagonist, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.SDS of cas: 445490-78-8

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On October 12, 2006, Roboisson, Pierre; Marugan Sanchez, Juan Jose published a patent.COA of Formula: C15H22N2O3 The title of the patent was Preparation of 4-substituted indoles for use as integrin antagonists. And the patent contained the following:

4-Substituted indoles I, wherein R is Ph or 3-pyridyl; X-Y is -CH2-O-, -CH2-NH-, or -CH2-CH2-; W can be II or III wherein R1 is hydrogen, alkyl, haloalkyl or halogen; R2 and R3 are independently hydrogen, halogen or alkyl; R4 and R5 are independently hydrogen, halogen, alkyl, alkoxy or aryl; R6 is hydrogen are prepared . Thus, IV was prepared and tested integrin antagonists, however, no biol. data was provided. Further, I may be used in the treatment of pathol. conditions mediated by avss3 and avss5 integrins, including but not limited to tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).COA of Formula: C15H22N2O3

The Article related to integrin antagonist human indole, indole preparation integrin antagonist, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.COA of Formula: C15H22N2O3

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On August 8, 2002, Lu, Tianbao; Lafrance, Louis Vincent; Markotan, Thomas P.; Marugan, Juan Jose; Marder, Victor J.; U’Prichard, David C.; Anaclerio, Beth M.; Guo, Zihong; Pan, Wenxi; Leonard, Kristi A. published a patent.Computed Properties of 445490-78-8 The title of the patent was Preparation of indoles and their use as αvβ3 and αvβ5 integrin antagonists. And the patent contained the following:

Title compounds I [R1-R5 = H, halo, alkyl, etc.; R6-R9 = H, alkyl, hydroxyalkyl, etc.; R10-R13 = H, OH, alkyl, etc.; R14 = H, or a functionality that acts as a prodrug; X = O, S, CH2, etc.; a, k, v = 0, 1; i, j, m, n = 0-4], their pharmaceutically acceptable salts, prodrugs and formulations were prepared For example, hydrogenation of acrylic ester II, prepared from 7-[2-[1-(2-Methoxycarbonyl-1-(pyridin-3-yl)vinyl)-1H-indol-5-yloxy]ethyl]-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-Bu ester and pyridin-3-ylpropynoic acid Me ester, followed by BOC deprotection, and ester hydrolysis provided claimed indole III. Indole III inhibited human αvβ3-vitronectin interaction at an IC50 of 0.24 nM, studies for an addnl. 6 examples are provided, ranging in values from 670 to 0.24 nM. Compounds I may be used in treatment of pathol. conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, inflammation, rheumatoid arthritis, etc.. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).Computed Properties of 445490-78-8

The Article related to preparation indole integrin antagonist antitumor antiinflammatory antirheumatic, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Computed Properties of 445490-78-8

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On November 7, 2002, Sanchez, Juan Jose Marugan; Marder, Victor J.; U’prichard, David C. published a patent.Quality Control of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate The title of the patent was Substituted benzofurans and benzothiophenes of use as integrin antagonists. And the patent contained the following:

Title compounds I [Y = O, S; X = O, S, CH2, NH; W = N heterocyclic, amino; Z = CR5R6(CH2)i(CR7R8)k(CH2)jCO2R9; R1-R4 = H, alkyl, haloalkyl, aryl, aralkyl; R5-R8 = H, OH, (un)substituted alkyl, alkoxy, cycloalkyl, aryl, heterocyclic; R5R7 = alkylene; R9 = H, alkyl, haloalkyl, aryl, aralkyl, aminoalkyl, alkoxyalkoxyalkyl, alkoxycarbonyloxyethyl; R10-R13 = H, (un)substituted alkyl, aryl; R10R11 = alkylene; i, j, m, n = 0-4; k = 0, 1] were prepared The compounds may be used in the treatment of pathol. conditions mediated by αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. Thus, the benzothiophene II was prepared from tert.-Bu 7-ethoxycarbonylmethyl-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylate and Et 3-(6-hydroxybenzo[b]thiophen-3-yl)propionate and had IC50 for inhibition of αvβ5-vitronectin in vitro of 8 nM. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).Quality Control of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate

The Article related to benzothiophenepropionate preparation vitronectin inhibitor, benzofuranpropionate preparation vitronectin inhibitor, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Quality Control of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem